EMEA-002525-PIP01-18

Key facts

Active substance
Moxetumomab pasudotox
Therapeutic area
Oncology
Decision number
P/0228/2019
PIP number
EMEA-002525-PIP01-18
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of hairy cell leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel. +46 8 55327591
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating